Back to Journals » Core Evidence » Volume 1-Issues 3 & 4 » Issue 4

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia

Authors Profit L

Published 30 June 2006 Volume 2006:1-Issues 3 & 4(4)

DOI https://doi.org/10.2147/CE.S7449


Louise Profit

Core Medical Publishing, Knutsford, UK

Introduction: Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts and bleeding episodes. Current therapy options are associated with unwanted side effects, and although patients initially respond to treatment the platelet count is not sustained in many individuals. There is a need for safe and well-tolerated treatments that provide a sustained platelet response.

Aims: This review summarizes the emerging evidence for the potential use of eltrombopag in the treatment of ITP in adults.

Disease and treatment: Eltrombopag is a nonpeptide, small molecular weight thrombopoietin receptor agonist that is orally administered. It mimics the activity of thrombopoietin, a cytokine that promotes growth and production of platelets, primarily inducing proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.

Profile: Eltrombopag is still in the early stages of development but initial phase I and phase II results are promising. Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. Its once-daily oral dosing regimen would also be an advantage over many of the existing therapies. It is expected that patients who have failed first-line therapy with corticosteroids and wish to avoid the need for a splenectomy, and patients with chronic refractory ITP, may benefit from eltrombopag treatment.

Key words: eltrombopag, evidence, immune thrombocytopenic purpura, outcomes, SB497115, thrombocytopenia, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]